RxDoctor Payments DataLook up a doctor →

Alan Kivitz, MD

Rheumatology · Duncansville, PANPI 1447259023

Payments from drug & device makers

$27,076,137in general payments, 2019–2025

Across 5,814 payments — averaging $4657.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$5.3M
  • Eli Lilly$4.2M
  • Amgen$3.9M
  • Pfizer$3M
  • UCB SA$2.3M
  • AbbVie$2.2M
  • plus $6.1M from 54 others
$116,574in research payments, 2019–2025

Across 83 payments — averaging $1404.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$46K
  • Pfizer$23K
  • Novartis$21K
  • UCB, Inc.$10K
  • Sanofi-aventis U.S. LLC$5K
  • Regeneron$3K
  • plus $8K from 5 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis271$5,328,965
Eli Lilly126$4,164,103
Amgen(2 entities)520$3,903,171
Pfizer458$2,963,942
UCB SA125$2,335,339
AbbVie1,343$2,243,925
Pacira Therapeutics, Inc.30$1,094,450
E.r. Squibb & Sons, L.L.C.69$962,652
Regeneron128$774,938
Gilead139$518,834
Navidea Biopharmaceuticals, Inc.10$405,963
Janssen Research & Development, LLC206$360,917
Modernatx, Inc.47$206,727
GSK225$189,075
Sanofi US Services Inc.140$181,505
Lilly USA, LLC226$143,000
Bristol Myers Squibb62$137,798
UCB, Inc.307$129,064
Teva Pharmaceuticals USA, Inc.31$115,588
Astrazeneca UK Limited11$110,647
Takeda Pharmaceuticals U.S.A., Inc.32$86,937
Hexal AG64$85,621
CSL Behring11$83,130
Radius Health, Inc.67$75,147
Dr.reddy's Laboratories,inc.16$69,730
Kiniksa Pharmaceuticals, Ltd.154$62,869
GRT US Holding, Inc.40$60,530
Sanofi98$48,833
Acadia Pharmaceuticals Inc8$46,136
Mallinckrodt Enterprises LLC13$30,134
Aurinia Pharma U.S., Inc.28$25,162
UCB GmbH1$16,147
Boehringer Ingelheim24$12,585
Novo Nordisk AS89$11,122
Kiniksa Pharmaceuticals International, PLC42$9,603
Tonix Medicines, Inc.7$8,777
Noven Pharmaceuticals, Inc.18$8,581
Servier Bioinnovation6$8,148
Johnson & Johnson(2 entities)283$7,501
Roche Products Limited2$6,863
Swedish Orphan Biovitrum AB3$6,495
Fresenius Kabi USA, LLC17$5,989
Janssen Scientific Affairs, LLC8$5,976
Regeneron Healthcare Solutions, Inc.9$4,109
UCB Biosciences Inc.1$3,000
Ironwood Pharmaceuticals, Inc3$2,870
Mallinckrodt Hospital Products Inc.38$2,860
Merck2$2,378
AstraZeneca(2 entities)73$2,100
EMD Serono, Inc.1$1,000
Averitas Pharma Inc.3$871
Sobi, Inc27$587
ANI Pharmaceuticals, Inc.29$581
Sanofi-aventis U.S. LLC18$413
Genentech USA, Inc.28$377
Progentec Diagnostics, Inc.1$370
Orion Corporation1$300
Organon21$272
Eli Lilly Export S.A. Puerto Rico Branch1$258
Kyowa Kirin, Inc.6$216

How this compares

$27,076,137 in reported general payments places this provider in the 95th percentile of 351 rheumatology providers in Pennsylvania.

See all rheumatology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024
$4,221,245
Medicare patients
1,014
Services billed
245,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other rheumatology in Duncansville

See the full list for Pennsylvania →

Where these figures come from

Is this you, or does something look wrong? →